Arunabio
Arunabio is a biotechnology company that develops a neural exosome platform for designing therapeutics to treat neurodegenerative diseases. The company platform develops neural exosomes that can cross the blood-brain barrier and enhance the body anti-inflammatory, self-repair, and protective mechanisms to treat a range of neurodegenerative conditions. By leveraging exosome biology, Arunabio aims to deliver…
Funding snapshot
About
Arunabio is a biotechnology company that develops a neural exosome platform for designing therapeutics to treat neurodegenerative diseases. The company platform develops neural exosomes that can cross the blood-brain barrier and enhance the body anti-inflammatory, self-repair, and protective mechanisms to treat a range of neurodegenerative conditions. By leveraging exosome biology, Arunabio aims to deliver therapeutic payloads directly to the brain, overcoming one of the most significant challenges in neurology drug development. The platform technology enables the development of treatments for conditions such as Alzheimer disease, Parkinson disease, and other neurodegenerative disorders where blood-brain barrier penetration is essential for therapeutic efficacy. Founded in 2003 and headquartered in Athens, Georgia, the company has raised approximately $33.1 million through Series B funding from investors including Eshelman Ventures, NIH, HHS, Georgia Research Alliance, and GRA Venture Fund.
Business model
Neurology > Drugs > Neurodegenerative > Diversified > Exosome Based,
Drug Delivery > Extracellular Vesicles Based > Exosome Based > For Neurodegenerative Diseases,
Genomics > Enabling Technologies > Kits and Reagents > Bioreagents,
Life Sciences Platforms and Tools > Research Assays > Drug Discovery
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.